Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Patients undergoing percutaneous coronary intervention (PCI) often require dual antiplatelet therapy (DAPT) to prevent stent thrombosis and myocardial infarction (MI).
• Atrial fibrillation (AF) affects 5-10% of PCI patients, necessitating oral anticoagulation (OAC) to prevent stroke.
• Combining OAC with DAPT significantly increases bleeding risk, creating a therapeutic dilemma.

Purpose of the Study:

• To review current evidence on balancing antithrombotic therapy in PCI patients with AF.
• To evaluate strategies aiming to reduce thrombotic events and bleeding complications.
• To identify knowledge gaps and ongoing research in this clinical area.

Main Methods:

• Review of existing clinical studies and trial data.
• Analysis of comparative effectiveness of different antithrombotic regimens.
• Synthesis of evidence regarding cardiovascular outcomes and bleeding events.

Main Results:

• Combining OAC with a single antiplatelet agent shows potential for reduced bleeding compared to DAPT.
• Current studies are often underpowered to definitively assess cardiovascular efficacy of reduced-antiplatelet strategies.
• Optimal antithrombotic regimen balancing efficacy and safety remains an area of active investigation.

Conclusions:

• The optimal antithrombotic strategy for PCI patients with AF requires careful consideration of both thrombotic and bleeding risks.
• Further research, including large clinical trials, is needed to establish the best approach.
• Ongoing trials are crucial for guiding clinical practice and improving patient outcomes.